Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Sequential Administration of Oral 6-Thioguanine (6-TG) After Methotrexate (MTX) in Patients With Relapsed Hodgkin's Disease (Phase II)

This study has been completed.
Sponsor:
Information provided by:
Memorial Sloan Kettering Cancer Center.
ClinicalTrials.gov Identifier:
NCT00587873
First received: December 26, 2007
Last updated: June 10, 2009
Last verified: June 2009
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: June 2009
  Primary Completion Date: December 2003 (Final data collection date for primary outcome measure)